Targeting K-Ras(G12C) mutations in cancer with a new treatment approach
Official title: Proximity-triggered, mutant-specific modification of K-Ras(G12C) with local polypharmaceutical release
Funded at Cold Spring Harbor Laboratory · NIH-11034459 · Data updated 2026-11-12
This study is testing a new treatment for certain types of cancer, like non-small cell lung and colorectal cancers, that have a specific mutation called K-Ras(G12C), and it aims to make the treatment work better while being gentler on the body.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cold Spring Harbor Laboratory NIH-funded |
| Lab location | 1 site (Cold Spring Harbor, United States) |
| Project start | February 3, 2025 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $269,280 |
| NIH project number | 1R21CA296712-01 |
| Project ID | NIH-11034459 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with non-small cell lung cancer or colorectal cancer that harbor the K-Ras(G12C) mutation.
✕Less likely to help
Patients without the K-Ras(G12C) mutation or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on developing a novel treatment for cancers driven by the K-Ras(G12C) mutation, which is common in non-small cell lung and colorectal cancers. The approach involves creating a multi-functional prodrug that can target multiple pathways simultaneously, potentially improving treatment efficacy while reducing toxicity. By using a unique method called group transfer, the treatment aims to covalently modify the K-Ras(G12C) protein, leading to its degradation and enhancing the release of cytotoxic agents. This innovative strategy seeks to overcome the limitations of current therapies and provide a more effective cancer treatment option.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment for patients with K-Ras(G12C) mutation-driven cancers, potentially improving survival rates and reducing side effects.
How similar studies have gone: While the approach of using targeted prodrugs is innovative, similar strategies targeting oncogenic mutations have shown promise in other studies, indicating potential for success.
Where this research is happening
-
Cold Spring Harbor Laboratory
Cold Spring Harbor, United States Active
Researchers
- Principal investigator: Moses, John Edward — Cold Spring Harbor Laboratory
- Study coordinator: Moses, John Edward
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.